Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4

Journal of Immunology

Volumn 164, Issue 4, 2000, Pages 1925-1933

  Reddy, Manjula P ^a   Kinney, Cheryl Ann S ^a   Chaikin, Margery A ^a,c   Payne, Angela ^a   Fishman Lobell, Jacqueline ^a   Tsui, Ping ^a   Dal Monte, Paul R ^a   Doyle, Michael L ^a   Brigham Burke, Michael R ^a   Anderson, Darrell ^b   Reff, Mitchell ^b   Newman, Roland ^b   Hanna, Nabil ^b   Sweet, Raymond W ^a   Truneh, Alemseged ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BIOGEN   (United States)

^c 3 Dimensional Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CLENOLIXIMAB; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; KELIXIMAB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; AUTOIMMUNE DISEASE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE;

EID: 0034651966     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.4.1925     Document Type: Article

References (41)

1. Sweet, R. W., A. Truneh, and W. A. Hendrickson. 1991. CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. Curr. Opin. Biotechnol. 2:622.
2. Deen, K. C., J. S. McDougal, R. Inacker, G. Folena-Wasserman, J. Arthos, J. Rosenberg, P. J. Maddon, R. Axel, and R. W. Sweet. 1988. A soluble of CD4 (T4) protein inhibits AIDS virus infection. Nature 331:82.
3. Panayi, G. S., J. S. Lanchbury, and G. H. Kingsley. 1992. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35:729.
4. Waldmann, H., and S. Cobbold. 1993. The use of monoclonal antibodies to achieve immunological tolerance. Immunol. Today 14:245.
5. Bach, J. F. 1993. Immunosuppressive therapy of autoimmune diseases. Immunol. Today 14:322.
6. Herzog, C., C. Walker, M. Wolfgang, P. Rieber, C. Reiter, G. Riethmuller, P. Wassmer, H. Stockinger, O. Madic, and W. J. Pichler. 1989. Anti-CD4 antibody treatment of patients with rhuematoid arthritis. I. Effect on clinical course and circulating T cells. J. Autoimmun. 2:627.
7. Hafler D. A., J. Ritz, S. Schlossman, and H. Weiner. 1988. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis: immunosuppressive effects and human anti-mouse responses. J. Immunol. 141:131.
8. Mathieson, P.W., S. P. Cobbold, and P. Hale. 1990. Monoclonal antibody therapy in systemic vasculitis. N. Engl. Med. 323:250.
9. Morel P., C. Vincent, G. Cordier, G. Panaye, E. Carosella, and J. P. Revillard. 1990. Anti-CD4 monoclonal antibody administration in renal transplanted patients. Clin. Immunol. Immunopathol. 56:311.
10. Newman R., J. Alberts, and D. Anderson. 1992. "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Bio/Technology 10:1415.
11. Van der Lubbe, P.A., C. Reiter, F. C. Breedveld, K. Druger, M. Schattenkirchner, M. E. Sanders, and G. Riethmuller. 1993. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheumatism 36: 1375.
12. 2 fragment of monoclonal antibody to L3T4. J. Immunol. 142:1470.
13. + cells. J. Immunol. 140:713.
14. Hutchings, P., L. O'Reilly, N. M. Parish, H. Waldman, and A. Cooke. 1992. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to cells in NOD mice. Eur. J. Immunol. 22:1913.
15. + T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9. 1) to human CD4. Clin. Immunol. Immunopathol. 84:73.
16. Kon, O. M., B. S. Sihra, C. H. Compton, T. B. Leonard, A. B. Kay and N. C. Barnes. 1998. Randomized, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352:1109.
17. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest, 5th Ed. U.S. Dept. of Health and Human Services, Bethesda, MD, NIH Publication no. 91-3242.
18. Doyle, M. L., M. Brigham-Burke, M. N. Blackburn, I. S. Brooks, T. M. Smith, R. Newman, M. Reff, W. F. Stafford III, R. W. Sweet, A. Truneh, et al. 1999. Measurement of protein interaction bioenergetics: application to structural variants of an anti-sCD4 antibody. Methods Enzymol., In press.
19. Jonak, L. Z., E. Henri, S. Trulli, C. P. Jensen, and K. A. Muirhead. 1992. Manipulation of human B cells to confer immortality. Hum. Antibody Hybridomas 3:177.
20. Boyum, A. 1983. Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium. Scand. J. Immunol. 17:429.
21. Gazzano, S., H. P. Ralph, T. C. Ryskamp, A. B. Chen, and V. R. Mukku. 1996. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J. Immunol. Methods 202:163.
22. Pulito, V. L., V. A. Roberts, and J. R. Adair. 1996. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J. Immunol. 156:2840.
23. Horneff, G., F. Emmrich, and G. R. Burmester. 1993. Advances in immunotherapy of rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Br. J. Rheumatol. 32:39.
24. Brett, S. J., W. Rowan, M. Smith, M. Batholomew, and J. P. Tite. 1997. Differential functional effects of a humanized anti-CD4 antibody on resting and activated human T cells. Immunology 91:346.
25. Deo, Y. M., R. F. Graziano, R. Repp, and J. G. J. vande Winkel. 1997. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies, Immunol. Today 18:127.
26. Nordstrom E, E. Moller, and M. Abedi-Vaugerdi. 1998. Induction of IgG rheumatoid factor (RF) production by antibody-antibody (RF-like) immune complexes: the role of T cells, complement and Fcγ receptors. J Autoimmun. 11:131.
27. Walker, C., C. Herzog, P. Rieber, G. Riethmuller, W. Muller, and W. J. Pichler, 1989. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells. J. Autoimmun. 2:643.
28. Mannie, M. D., S. K. Rendall, P. V. Arnold, J. P. Nardella, and G. A. White. 1996. Anergy-associated T cell antigen presentation: a mechanism of infectious tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 157:1062.
29. Fanger, M. W., L. Shen, R. F. Graziano, P. M. Guyre. 1989. Cytotoxicity mediated by human Fc receptor for IgG. Immuol. Today 10:92.
30. Guyre, P. M., R. F. Graziano, B. A. Vance, P. M. Morganelli, and M. W. Fanger. 1989. Monoclonal antibodies that bind to distinct epitopes or FcγRI are able to trigger receptor function. J. Immunol. 143:1650.
31. Burton, R., and J. M. Woof. Human effector functions. 1992. Adv. Immunol. 51:1.
32. Duncan, A. R., J. M. Woof, L. J. Patridge, and G. Winter. 1988. Localization of the binding site for the high-affinity Fc receptor on IgG. Nature 332:563.
33. Lund, J., G. Winter, P. T. Jones, P. T. Pound, M. R. Walker, P. J. Artymiuk, Y. Arta, D. R. Burton, R. Jefferies, and J. M. Woof. 1991. Human FcγRII interact with distinct but overlapping sites on human IgG. J. Immunol. 147:2657.
34. Alegre, M.-L., A. M. Collins, V. L. Pulito, R. A. Brosius, W. C. Olson, R. A. Zivin, R. Knowles, J. R. Thislethwaite, L. K. Jolliffe, and J. A. Bluestone. 1992. Effect of single amino acid mutation on the activating and immunosuppressive properties of a humanized OKT3 monoclonal antibody. J. Immunol. 148:3461.
35. Angal, S., D. J King, M. W. Bodmer, A. Turner, A. D. G. Lawson, G. Roberts, B. Pedle, and J. R. Adair. 1993. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30:105.
36. Issacs, J. D., M. G. Wing, D. J. Greenwood, L. B. Hazelman, G. Hale, and H. Waldmann. 1996. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106:427.
37. Garred, P., T. E. Michaelson, and A. Aase. 1989. The IgG subclass pattern of complement activation depends upon density and antibody and complement activation. Scand. J. Immunol. 30:379.
38. Bartholomew, M., S. Brett, K. Barber, C. Rossman, S. Crowe, and J. Tite. 1995. Functional analysis of the effects of a fully humanized anti-CD4 antibody on resting and activating human T cells. Immunology 85:41.
39. Bolt, S., E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S. D. Gorman, M. Clark, and H. Waldmann. 1993. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23:403.
40. + T cell depletion is not required. Immunology, In press.
41. Choy, E. H. S., G. H. Kingsley, and G. S. Panayi. 1998. Monoclonal antibody therapy in rheumatoid arthritis. Br. J. Rheumatol. 37:484.